Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
To offer patients with oligomenorrhoea or amenorrhoea an alternative to frozen embryo
transfer in an artificial cycle, endometrial preparation using letrozole may be a valuable
option. Letrozole, a potent, reversible nonsteroidal aromatase inhibitor with relatively
short half-life, can successfully induce ovulation without any adverse anti-estrogenic
effects and thus without affecting the endometrium. The use of letrozole typically results in
monofollicular growth and this reduces the effect of supraphysiological levels of estrogen on
the endometrium and embryo. The purpose of this study is to compare a frozen-thawed embryo
transfer in an artificial cycle with a letrozole-induced ovulatory cycle, specifically in
PCOS patients. The primary outcome is early pregnancy loss.